Drug Profile


Alternative Names: RWJ 21757

Latest Information Update: 08 Jun 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson
  • Developer Johnson & Johnson; Nonindustrial source
  • Class Antineoplastics; Purine nucleosides; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Endometriosis
  • Discontinued Cancer

Most Recent Events

  • 08 Jun 2001 No-Development-Reported for Endometriosis in USA (Unknown route)
  • 18 Jan 1999 A preclinical study has been added to the Women's health pharmacodynamics section
  • 18 Sep 1998 Preclinical development for Endometriosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top